Cancer stem cells in multiple myeloma

Cancer Letters

Volumn 277, Issue 1, 2009, Pages 1-7

  Ghosh, Nilanjan ^a   Matsui, William ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

B cells; Hedgehog; Immune therapy; Multiple myeloma; Stem cells

Indexed keywords

CANCER IMMUNOLOGY; CANCER STEM CELL; CELL HETEROGENEITY; CLONOGENESIS; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ERINACEIDAE;

EID: 61849148751     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.005     Document Type: Review

References (83)

1. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T.C.-C.J., Minden M., Paterson B., Caligiuri M.A., and Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
2. Al Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 3983-3988
3. Zucchi I., Sanzone S., Astigiano S., Pelucchi P., Scotti M., Valsecchi V., Barbieri O., Bertoli G., Albertini A., Reinbold R.A., and Dulbecco R. The properties of a mammary gland cancer stem cell. Proc. Natl. Acad. Sci. USA 104 (2007) 10476-10481
4. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., and Dirks P.B. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
5. Dalerba P., Dylla S.J., Park I.k., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., and Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 104 (2007) 10158-10163
6. O'Brien C.A., Pollett A., Gallinger S., and Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
7. Drewinko B., Alexanian R., Boyer H., Barlogie B., and Rubinow S.I. The growth fraction of human myeloma cells. Blood 57 (1981) 333-338
8. Bergsagel D.E., and Valeriote F.A. Growth characteristics of a mouse plasma cell tumor. Cancer Res. 28 (1968) 2187-2196
9. TILL J.E., and McCulloch E.A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14 (1961) 213-222
10. Park C.H., Bergsagel D.E., and McCulloch E.A. Mouse myeloma tumor stem cells: a primary cell culture assay. J. Natl. Cancer Inst. 46 (1971) 411-422
11. Hamburger A.W., and Salmon S.E. Primary bioassay of human tumor stem cells. Science 197 (1977) 461-463
12. Hamburger A., and Salmon S.E. Primary bioassay of human myeloma stem cells. J. Clin. Invest. 60 (1977) 846-854
13. Mellstedt H., Hammarstrom S., and Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin. Exp. Immunol. 17 (1974) 371-384
14. Billadeau D., Ahmann G., Greipp P., and Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med. 178 (1993) 1023-1031
15. Bakkus M.H., Van R., Van Camp I.B., and Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br. J. Haematol. 87 (1994) 68-74
16. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 85 (1995) 436-447
17. Chen B.J., and Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 87 (1996) 1972-1976
18. Szczepek A.J., Seeberger K., Wizniak J., Mant M.J., Belch A.R., and Pilarski L.M. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92 (1998) 2844-2855
19. + cells in the peripheral blood of a patient with multiple myeloma. Br. J. Haematol. 105 (1999) 265-267
20. Pilarski L.M., Giannakopoulos N.V., Szczepek A.J., Masellis A.M., Mant M.J., and Belch A.R. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clin. Cancer Res. 6 (2000) 585-596
21. + cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br. J. Haematol. 117 (2002) 852-859
22. Bergui L., Schena M., Gaidano G., Riva M., and Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med. 170 (1989) 613-618
23. Caligaris-Cappio F., Bergui L., Tesio L., Pizzolo G., Malavasi F., Chilosi M., Campana D., van C.B., and Janossy G. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J. Clin. Invest. 76 (1985) 1243-1251
24. Kuppers R., Klein U., Hansmann M.L., and Rajewsky K. Cellular origin of human B-cell lymphomas. N. Engl. J. Med. 341 (1999) 1520-1529
25. Bakkus M.H., Heirman C., Van Riet I., Van Camp B., and Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80 (1992) 2326-2335
26. Sahota S., Hamblin T., Oscier D.G., and Stevenson F.K. Assessment of the role of clonogenic B lymphocytes in the pathogenesis of multiple myeloma. Leukemia 8 (1994) 1285-1289
27. Vescio R.A., Cao J., Hong C.H., Lee J.C., Wu C.H., Der D.M., Wu V., Newman R., Lichtenstein A.K., and Berenson J.R. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J. Immunol. 155 (1995) 2487-2497
28. Rasmussen T., Jensen L., and Johnsen H.E. The clonal hierarchy in multiple myeloma. Acta Oncol. 39 (2000) 765-770
29. Rasmussen T., Lodahl M., Hancke S., and Johnsen H.E. In multiple myeloma clonotypic. Leuk. Lymphoma 45 (2004) 1413-1417
30. Yaccoby S., Barlogie B., and Epstein J. Primary myeloma cells growing in SCID-hu mice. A model for studying the biology and treatment of myeloma and its manifestations. Blood 92 (1998) 2908-2913
31. Yaccoby S., and Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94 (1999) 3576-3582
32. Pilarski L.M., Hipperson G., Seeberger K., Pruski E., Coupland R.W., and Belch A.R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95 (2000) 1056-1065
33. Pilarski L.M., Seeberger K., Coupland R.W., Eshpeter A., Keats J.J., Taylor B.J., and Belch A.R. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp. Hematol. 30 (2002) 221-228
34. Matsui W., Huff C.A., Wang Q., Malehorn M.T., Barber J., Tanhehco Y., Smith B.D., Civin C.I., and Jones R.J. Characterization of clonogenic multiple myeloma cells. Blood 103 (2004) 2332-2336
35. Luckey C.J., Bhattacharya D., Goldrath A.W., Weissman I.L., Benoist C., and Mathis D. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 103 (2006) 3304-3309
36. Tomayko M.M., Anderson S.M., Brayton C.E., Sadanand S., Steinel N.C., Behrens T.W., and Shlomchik M.J. Systematic comparison of gene expression between murine memory and naive B cells demonstrates that memory B cells have unique signaling capabilities. J. Immunol. 181 (2008) 27-38
37. Chang J.T., Palanivel V.R., Kinjyo I., Schambach F., Intlekofer A.M., Banerjee A., Longworth S.A., Vinup K.E., Mrass P., Oliaro J., Killeen N., Orange J.S., Russell S.M., Weninger W., and Reiner S.L. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315 (2007) 1687-1691
38. Schittek B., and Rajewsky K. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors. Nature 346 (1990) 749-751
39. Decker D.J., Linton P.J., Zaharevitz S., Biery M., Gingeras T.R., and Klinman N.R. Defining subsets of naive and memory B cells based on the ability of their progeny to somatically mutate in vitro. Immunity 2 (1995) 195-203
40. Heyzer-Williams L.J., Cool M., and Heyzer-Williams M.G. Antigen-specific B cell memory: expression and replenishment of a novel B220-memory B cell compartment. J. Exp. Med. 191 (2000) 1149-1166
41. Aviszus K., Zhang X., and Wysocki L.J. Silent development of memory progenitor B cells. J. Immunol. 179 (2007) 5181-5190
42. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997) 730-737
43. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., and Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 100 (2003) 15178-15183
44. Matsui W., Wang Q., Barber J.P., Brennan S., Smith B.D., Borrello I., McNiece I., Lin L., Ambinder R.F., Peacock C., Watkins D.N., Huff C.A., and Jones R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68 (2008) 190-197
45. Agematsu K., Hokibara S., Nagumo H., and Komiyama A. CD27: a memory B-cell marker. Immunol. Today 21 (2000) 204-206
46. Shmelkov S.V., Butler J.M., Hooper A.T., Hormigo A., Kushner J., Milde T., St C.R., Baljevic M., White I., Jin D.K., Chadburn A., Murphy A.J., Valenzuela D.M., Gale N.W., Thurston G., Yancopoulos G.D., D'Angelica M., Kemeny N., Lyden D., and Rafii S. CD133 expression is not restricted to stem cells, and both CD133 and CD133 metastatic colon cancer cells initiate tumors. J. Clin. Invest. 12 (2003) 1-2
47. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., and Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 67 (2007) 1030-1037
48. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 (2007) 313-323
49. Namikawa R., Ueda R., and Kyoizumi S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 82 (1993) 2526-2536
50. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 351 (2004) 1860-1873
51. Pilarski L.M., and Belch A.R. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 83 (1994) 724-736
52. Kiel K., Cremer F.W., Rottenburger C., Kallmeyer C., Ehrbrecht E., Atzberger A., Hegenbart U., Goldschmidt H., and Moos M. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transpl. 23 (1999) 1019-1027
53. + B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br. J. Haematol. 106 (1999) 545-552
54. Rasmussen T., Jensen L., Honore L., and Johnsen H.E. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood 96 (2000) 4357-4359
55. Pilarski L.M., Szczepek A.J., and Belch A.R. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 90 (1997) 3751-3759
56. Goodell M.A. Multipotential stem cells and 'side population' cells. Cytotherapy 4 (2002) 507-508
57. Kastan M.B., Schlaffer E., Russo J.E., Colvin O.M., Civin C.I., and Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75 (1990) 1947-1950
58. Lobo N.A., Shimono Y., Qian D., and Clarke M.F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23 (2007) 675-699
59. Taipale J., and Beachy P.A. The hedgehog and Wnt signalling pathways in cancer. Nature 411 (2001) 349-354
60. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
61. Peacock C.D., Wang Q., Gesell G.S., Corcoran-Schwartz I.M., Jones E., Kim J., Devereux W.L., Rhodes J.T., Huff C.A., Beachy P.A., Watkins D.N., and Matsui W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. USA 104 (2007) 4048-4053
62. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den N.E., Salles G., Gaulard P., Reyes F., Lederlin P., and Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346 (2002) 235-242
63. Schulz H., Bohlius J.F., Trelle S., Skoetz N., Reiser M., Kober T., Schwarzer G., Herold M., Dreyling M., Hallek M., and Engert A. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl. Cancer Inst. 99 (2007) 706-714
64. Treon S.P., Pilarski L.M., Belch A.R., Kelliher A., Preffer F.I., Shima Y., Mitsiades C.S., Mitsiades N.S., Szczepek A.J., Ellman L., Harmon D., Grossbard M.L., and Anderson K.C. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J. Immunother. 25 (2002) 72-81
65. Bensinger W.I., and Gahrton G. Allogeneic hematopoietic cell transplantation for multiple myeloma. In: Thomas E.D., Blume K.G., and Forman S.G. (Eds). Hematopoietic Stem Cell Transplantation (1999), Blackwell Scientific Publications, Boston 887-891
66. Huff C.A., Fuchs E.J., Noga S.J., O'Donnell P.V., Ambinder R.F., Diehl L., Borrello I., Vogelsang G.B., Miller C.B., Flinn I.A., Brodsky R.A., Marcellus D., and Jones R.J. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol. Blood Marrow Transpl. 9 (2003) 312-319
67. Rasmussen T., Hansson L., Osterborg A., Johnsen H.E., and Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101 (2003) 4607-4610
68. Lim S.H., and Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 83 (1999) 215-222
69. Reichardt V.L., Milazzo C., Brugger W., Einsele H., Kanz L., and Brossart P. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 88 (2003) 1139-1149
70. Bendandi M., Rodriguez-Calvillo M., Inoges S., Lopez-Diaz de C.A., Perez-Simon J.A., Rodriguez-Caballero A., Garcia-Montero A., Almeida J., Zabalegui N., Giraldo P., San M.J., and Orfao A. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma 47 (2006) 29-37
71. Curti A., Tosi P., Comoli P., Terragna C., Ferri E., Cellini C., Massaia M., D'Addio A., Giudice V., Di B.C., Cavo M., Conte R., Gugliotta G., Baccarani M., and Lemoli R.M. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br. J. Haematol. 139 (2007) 415-424
72. Spisek R., Kukreja A., Chen L.C., Matthews P., Mazumder A., Vesole D., Jagannath S., Zebroski H.A., Simpson A.J.G., Ritter G., Durie B., Crowley J., Shaughnessy Jr. J.D., Scanlan M.J., Gure A.O., Barlogie B., and Dhodapkar M.V. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J. Exp. Med. 204 (2007) 831-840
73. Noonan K., Matsui W., Serafini P., Carbley R., Tan G., Khalili J., Bonyhadi M., Levitsky H., Whartenby K., and Borrello I. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 65 (2005) 2026-2034
74. Jamieson C.H.M., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., Sawyers C.L., and Weissman I.L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351 (2004) 657-667
75. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., Golub T.R., and Armstrong S.A. Transformation from committed progenitor to leukaemia stem cell initiated by MLLGÇôAF9. Nature 442 (2006) 818-822
76. Liu S., Ginestier C., Charafe-Jauffret E., Foco H., Kleer C.G., Merajver S.D., Dontu G., and Wicha M.S. BRCA1 regulates human mammary stem/progenitor cell fate. Proc. Natl. Acad. Sci. 105 (2008) 1680-1685
77. Barabe F., Kennedy J.A., Hope K.J., and Dick J.E. Modeling the initiation and progression of human acute leukemia in mice. Science 316 (2007) 600-604
78. Scadden D.T. The stem-cell niche as an entity of action. Nature 441 (2006) 1075-1079
79. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., and Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 317 (2007) 337
80. Hideshima T., and Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer 2 (2002) 927-937
81. Fonseca R., Blood E., Rue M., Harrington D., Oken M.M., Kyle R.A., Dewald G.W., Van Ness B., Van Wier S.A., Henderson K.J., Bailey R.J., and Greipp P.R. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
82. Zhan F., Huang Y., Colla S., Stewart J.P., Hanamura I., Gupta S., Epstein J., Yaccoby S., Sawyer J., Burington B., Anaissie E., Hollmig K., Pineda-Roman M., Tricot G., van Rhee F., Walker R., Zangari M., Crowley J., Barlogie B., and Shaughnessy Jr. J.D. The molecular classification of multiple myeloma. Blood 108 (2006) 2020-2028
83. Hanamura I., Stewart J.P., Huang Y., Zhan F., Santra M., Sawyer J.R., Hollmig K., Zangarri M., Pineda-Roman M., van Rhee F., Cavallo F., Burington B., Crowley J., Tricot G., Barlogie B., and Shaughnessy Jr. J.D. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108 (2006) 1724-1732